Pentoxifylline: A Versatile Off-Patent Medication Best Not Overlooked by Powell, Robert Charles

Pentoxifylline: A Versatile Off-Patent Medication Best Not Overlooked (Paperback) (ISBN-13: 9781511673051)

Vendor: Robert Charles Powell
Product type: Books
Format: Paperback
$19.99
$19.99
$19.99
Subtotal: $19.99
Pentoxifylline: A Versatile Off-Patent Medication Best Not Overlooked by Powell, Robert Charles

Pentoxifylline: A Versatile Off-Patent Medication Best Not Overlooked

$19.99
Pentoxifylline: A Versatile Off-Patent Medication Best Not Overlooked by Powell, Robert Charles

Pentoxifylline: A Versatile Off-Patent Medication Best Not Overlooked

$19.99
Format: Paperback
Description
Description
x
Pentoxifylline once was labeled as a treatment for "leg cramps" - "intermittent claudication". That original view has become almost irrelevant. The anti-inflammatory, immune modulating, and steroid-sparing effects of "pentox" stretch far beyond its vascular effects. Pentox is now known to treat - "off label" - kidney, liver, heart, & lung disorders - bone, joint, brain, & pain disorders - fibrotic, skin, & radiation-induced disorders - blood cell, pancreatic, & intestinal disorders - muscle, cancerous, & infectious disorders. Off-label use of pentox is both widespread and growing - with most of the uses relating to enhancement of blood flow or to reduction of inflammation. This monograph coherently assembles over 300 abstracts of the recent medical literature.

Author: Robert Charles Powell
ISBN-10: 1511673052
ISBN-13: 9781511673051
Publisher: Createspace Independent Publishing Platform
Language: English
Published: 04/10/2015
Pages: 112
Format: Paperback
Weight: 0.35lbs
Size: 9.00h x 6.00w x 0.23d
By Robert Charles Powell
By Robert Charles Powell
x
Robert Charles Powell, MD, PhD, is a physician & historian who, among other things, has been studying the development of uses of "pentox" for over a decade. Among his intriguing findings - here documented - is that "after pentoxifylline went off-patent in the United States in 1998 the supposedly more prestigious journals lost interest - while the generally non-Anglo-American journals retained or gained interest". "One has to wonder if this skewed publication pattern occurs concerning other medications - that certain editors, authors, and readers become less interested once a medication is not being promoted by a pharmaceutical company, while certain other editors, authors, and readers become more interested once the price of a medication is no longer supported by a patent."

Recently Viewed Products